"rationale","instanceType","label","description","id","name","uuid:ID"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign","","The main design for the study","StudyDesign_1","Study Design 1","863024ba-632a-4f15-866c-d39a1ecf3175"
